- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | Genflow-CEO kauft Aktien und hält nun 36% des Unternehmens | 2 | Investing.com Deutsch | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 28.03. | Genflow CEO buys shares, holds 36% of the company | 2 | Investing.com | ||
| 28.03. | Genflow Biosciences PLC Announces Holding in Company | 174 | ACCESS Newswire | LONDON, UNITED KINGDOM / ACCESS Newswire / March 28, 2025 / 1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason for NotificationAn acquisition or disposal... ► Artikel lesen | |
| 28.03. | Genflow Biosciences - Holding in Company | - | RNS | ||
| 28.03. | Genflow Biosciences PLC Announces Director Dealings | 135 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 28.03. | Genflow Biosciences - Director Dealings | 2 | RNS | ||
| 26.03. | Genflow Biosciences PLC Announces Institutional Investment | 130 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 26.03. | Genflow Biosciences - Institutional Investment | 4 | RNS | ||
| 20.02. | Genflow Biosciences PLC Announces Advancements in SIRT6 Variant Patent Application | 138 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / February 20, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen | |
| 20.02. | Genflow Biosciences - Advancements in SIRT6 Variant Patent Application | 1 | RNS | ||
| 13.01. | Genflow Biosciences PLC Announces Holding(s) in Company - 2 | 206 | ACCESS Newswire | TR-1: Standard form for notification of major holdings LONDON, UNITED KINGDOM / ACCESSWIRE / January 13, 2025 / 1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2.... ► Artikel lesen | |
| 13.01. | Genflow Biosciences PLC Announces Holding(s) in Company - 1 | 169 | ACCESS Newswire | TR-1: Standard form for notification of major holdings LONDON, UNITED KINGDOM / ACCESSWIRE / January 13, 2025 / 1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2.... ► Artikel lesen | |
| 06.01. | Genflow Biosciences enters 2025 with confidence in research progress | 2 | Alliance News | ||
| 06.01. | Genflow Biosciences PLC Announces 2024 Highlights | 215 | ACCESS Newswire | Genflow Biosciences Plc("Genflow" or "the Company")A Look Back at an Exciting 2024 LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / 2024 has been an incredible year for Genflow as we advance... ► Artikel lesen | |
| 06.01. | Genflow Biosciences - 2024 Highlights | - | RNS | ||
| 22.10.24 | Genflow Biosciences secures EUR4 million for liver disease treatment | 8 | Alliance News | ||
| 22.10.24 | Genflow Biosciences PLC: Genflow Secures Non-Dilutive Financial Support | 183 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 22.10.24 | Genflow Biosciences - Genflow Secures Non-Dilutive Financial Support | 3 | RNS | ||
| 30.09.24 | Genflow Biosciences PLC Announces Half-year Report | 342 | ACCESS Newswire | LONDON, UNITED KINGDOM / ACCESSWIRE / September 30, 2024 / Genflow (LSE:GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024.Chairman's StatementIt is with... ► Artikel lesen | |
| 27.06.24 | Genflow Biosciences Plc Announces Result of AGM | 297 | ACCESS Newswire | LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 46,220 | 0,00 % | Tempus AI, Inc. (NASDAQ:TEM) Sees Significant Increase in Short Interest | ||
| EDGEWISE THERAPEUTICS | 13,600 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
| QIAGEN | 36,420 | +0,61 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 43,110 | -7,33 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,425 | 0,00 % | Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard | ||
| AVIDITY BIOSCIENCES | 28,120 | -5,54 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 16,180 | -2,53 % | Arcutis Biotherapeutics, Inc.: Arcutis and Padagis Agree to Stay Patent Lawsuit | WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| OSR HOLDINGS | 2,430 | 0,00 % | OSR Holdings Inc.: OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate ... | SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,800 | 0,00 % | Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March | ||
| CG ONCOLOGY | 18,750 | -16,41 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,470 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 13,415 | +2,80 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen | |
| IMMUNOVANT | 15,770 | 0,00 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | 0,00 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
| BIONTECH | 82,50 | -1,37 % | BioNTech-Aktie: Das tragische Ende! | News von Trading-Treff.de Für die BioNTech sieht es nach einem tragischen Ende des Aufwärtsmarsches aus. Die Mainzer haben auch am Donnerstag einen Abschlag in Höhe von mehr als -1,9 % hinnehmen müssen.... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,012 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.
